Abdullah Sakİn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8396638/publications.pdf

Version: 2024-02-01

70 244 8 11 papers citations h-index g-index

73 73 73 415
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 865-875.	1.2	1
2	Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. Journal of Gastrointestinal Cancer, 2022, 53, 282-288.	0.6	2
3	The Predictive Value of Baseline Volumetric PET/CT Parameters on Treatment Response and Prognosis in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. Journal of Gastrointestinal Cancer, 2022, 53, 341-347.	0.6	4
4	Factors Affecting Survival in Operated Esophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Cancer, 2022, 53, 439-445.	0.6	1
5	Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study. Oncology Research and Treatment, 2022, 45, 254-261.	0.8	2
6	The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. Journal of Chemotherapy, 2022, , 1-10.	0.7	0
7	Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG)ÂStudy. Cancer Investigation, 2022, 40, 199-209.	0.6	1
8	First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	0
9	Predictive Factors of Complete Tumor Response to First Line Chemotherapy in Patients with Extensive-stage Small Cell Lung Cancer. Bagcilar Medical Bulletin, 2022, .	0.0	O
10	Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study Journal of Clinical Oncology, 2022, 40, e23542-e23542.	0.8	0
11	Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wil‡ld-type patients treated with biologics second-line mCRC Journal of Clinical Oncology, 2022, 40, e15562-e15562.	0.8	O
12	The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced Esophageal Squamous Cell Carcinoma treated with definitive chemoradiotherapy. Surgical Oncology, 2022, 43, 101809.	0.8	5
13	Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer. Tumori, 2021, 107, 416-423.	0.6	3
14	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. Journal of Gastrointestinal Cancer, 2021, 52, 932-939.	0.6	1
15	Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?. Current Problems in Cancer, 2021, 45, 100619.	1.0	5
16	Does the Waiting Period for Genetic Tests Affect the Prognosis in Chemotherapy-Treated de novo Metastatic Non-Small Cell Lung Cancer Patients without a Driver Mutation?. Oncology Research and Treatment, 2021, 44, 12-19.	0.8	2
17	Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?. Current Problems in Cancer, 2021, 45, 100670.	1.0	2
18	The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology, 2021, 27, 26-34.	1.0	9

#	Article	IF	Citations
19	Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study. The Journal of Breast Health, 2021, 17, 123-127.	0.4	7
20	Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncology, 2021, 17, 1611-1624.	1.1	1
21	124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey. Annals of Oncology, 2021, 32, S74.	0.6	1
22	P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study. Annals of Oncology, 2021, 32, S174.	0.6	0
23	The conversion of RAS status in metastatic colorectal cancer patients after firstâ€line biological agent treatment. Colorectal Disease, 2021, 23, 206-212.	0.7	0
24	The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy. Current Problems in Cancer, 2020, 44, 100485.	1.0	7
25	Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: An observational study. Journal of Oncology Pharmacy Practice, 2020, 26, 619-631.	0.5	3
26	Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?. Supportive Care in Cancer, 2020, 28, 2273-2282.	1.0	17
27	Factors affecting survival and treatment efficacy in breast cancer patients with bone marrow metastasis. Breast Journal, 2020, 26, 815-818.	0.4	3
28	The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy. Nutrition and Cancer, 2020, 73, 1-8.	0.9	2
29	The Clinical Importance of Androgen Receptor Status in Response to Neoadjuvant Chemotherapy in Turkish Patients with Local and Locally Advanced Breast Cancer. Oncology Research and Treatment, 2020, 43, 435-440.	0.8	6
30	The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Journal of Oncology Pharmacy Practice, 2020, 26, 1611-1620.	0.5	5
31	Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG). Indian Journal of Hematology and Blood Transfusion, 2020, 36, 640-645.	0.3	1
32	The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer. Journal of Oncology Pharmacy Practice, 2020, 26, 1415-1420.	0.5	3
33	Prognostic significance of neutrophil to lymphocyte ratio in esophageal squamous cell carcinoma. İstanbul Kuzey Klinikleri, 2020, 8, 435-442.	0.1	6
34	Factors affecting survival in operated pancreatic cancer; Does tumor localization have a significant effect on treatment outcomes?. İstanbul Kuzey Klinikleri, 2020, 7, 487-493.	0.1	1
35	The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics, 2020, 16, 816.	0.3	2
36	Adrenocortical Carcinoma: Single Center Experience. European Archives of Medical Research, 2020, 36, 52-56.	0.0	0

#	Article	IF	Citations
37	The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2723-2731.	0.5	O
38	The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2723-2731.	0.5	2
39	The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer. Oncology Research and Treatment, 2019, 42, 506-514.	0.8	17
40	Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent,) Tj ETQq0 0 and Treatment, 2019, 42, 516-522.	0 rgBT /Ov 0.8	verlock 10 1 10
41	The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Science, 2019, 5, 85-89.	0.1	O
42	Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population. International Journal of Breast Cancer, 2019, 2019, 1-7.	0.6	18
43	Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Lung Cancer, 2019, 133, 38-44.	0.9	3
44	Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors. Journal of Surgical Research, 2019, 241, 170-177.	0.8	7
45	Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy. Scientific Reports, 2019, 9, 3959.	1.6	16
46	P2.01-64 Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S664-S665.	0.5	0
47	Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-na $\tilde{\mathbb{A}}$ -ve breast cancer: real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 2019, 83, 131-143.	1.1	8
48	Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. Cancer Chemotherapy and Pharmacology, 2019, 83, 115-122.	1.1	14
49	Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1879-1885.	0.5	9
50	Factors Affecting Survival in Esophageal Squamous Cell Carcinoma: Single Center Experience. İstanbul Kuzey Klinikleri, 2019, 7, 267-274.	0.1	1
51	Non-urothelial Bladder Cancers: Single Center Experience. European Archives of Medical Research, 2019, 35, 162-166.	0.0	O
52	Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder. Oncology Research and Treatment, 2018, 41, 220-225.	0.8	3
53	P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey. Journal of Thoracic Oncology, 2018, 13, S477-S478.	0.5	O
54	Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3597-3603.	0.5	8

#	Article	IF	CITATIONS
55	Prognostic significance of primary tumor localization in stage II and III colon cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 410-420.	0.8	5
56	Effectiveness and tolerability of FOLFIRINOX regime in metastatic pancreas cancer disease. The Medical Journal of Okmeydani Training and Research Hospital, 2018, , .	0.0	0
57	Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. International Urology and Nephrology, 2017, 49, 1041-1047.	0.6	11
58	Paroxysmal Nocturnal Haemoglobinuria Presenting with Acute Kidney Injury: A Case Report. The Medical Journal of Okmeydani Training and Research Hospital, 2017, , .	0.0	0
59	Chylothorax due to lymphadenitis of tuberculosis: Case Report. İstanbul Kuzey Klinikleri, 2016, 3, 225-228.	0.1	5
60	Evaluation of Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Expression Levels in Patients with Chronic Lymphocytic Leukemia. Turkish Journal of Haematology, 2016, 33, 335-338.	0.2	2
61	The frequency of polyneuropathy and comparison of laboratory parameters in patients with multiple myeloma. Dicle Medical Journal, 2016, 42, .	0.2	O
62	Delayed Paraganglioma Diagnosis: A Case Report and Literature Update. İstanbul Medical Journal, 2016, 16, 162-164.	0.1	0
63	Factors Affecting Survival in Small Cell Lung Cancer. Electronic Journal of General Medicine, 2016, 13,	0.3	0
64	A Rare Cause of Pleural Effusion: Adult Onset Still's Disease. İstanbul Kuzey Klinikleri, 2015, 2, 155-158.	0.1	0
65	Cerebral Amyloid Angiopathy: A Case Report and Literature Update. Haseki Tip Bulteni, 2015, 53, 92-94.	0.2	0
66	Tracheobronchial amiloidosis. İstanbul Medical Journal, 2015, 16, 119-121.	0.1	1
67	Aggressive Natural Killer Cell Leukemia: A Case Report and Literature Update. İstanbul Medical Journal, 2015, 16, 130-132.	0.1	0
68	The Relationship between Soluble Tumor Necrosis Factor-like Weak Inducer of Apoptosis Levels and Cardiac Functions in Peritoneal Dialysis Patients. European Journal of Inflammation, 2014, 12, 429-437.	0.2	1
69	Spontaneous Renal Cholesterol Crystal Embolism In A Patient with Functionally Solitary Kidney. Electronic Journal of General Medicine, 2014, 11, .	0.3	O
70	Çölyak Hastalığında Geçici Sensorinöral İşitme Kaybı: Rastlantısal Bir Bulgu Mu?. Haseki Tip Bu 51, 190-192.	teni, 2013	' o